Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Hospital de Clinicas de Porto Alegre |
---|---|
Information provided by: | Hospital de Clinicas de Porto Alegre |
ClinicalTrials.gov Identifier: | NCT00848770 |
This is a controlled clinical trial among non thrombolysed acute ischemic stroke patients to determine the effects of three levels of arterial pressure on death and neurological disability. After the admission in the vascular unit of the Emergency Department the patients are randomized to maintain during the first 24h the Systolic Arterial Pressure in tree levels of pressure: 140 to 160 mmHg; 161 to 180 mmHg and 181 to 200 mmHg. The end point of the study is the Modified Rankin score and mortality in three month after the discharge.
Condition | Intervention |
---|---|
Stroke, Acute |
Drug: Esmolol, Sodium Nitroprussiate (NPS) or Norepinephrine (NOR) Drug: Esmolol, NPS or NOR Drug: manipulation of SAP |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Manipulation of Arterial Pressure Early in Non Thrombolysed Acute Ischemic Stroke: Effects on Death and Neurological Disability |
Estimated Enrollment: | 240 |
Study Start Date: | January 2008 |
Estimated Study Completion Date: | December 2010 |
Estimated Primary Completion Date: | December 2010 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1, 140 to 160 mmHg: Active Comparator
Esmolol, NPS or NOR
|
Drug: Esmolol, Sodium Nitroprussiate (NPS) or Norepinephrine (NOR)
Esmolol(2,5g /10ml + SG5% 240ml = 10mg/ml). Start with a bolus of 500mcg/kg in 1 min (ou 0,5mg/kg)and maintain the dose of 50mcg/kg/min (or 0,05mg/kg/min). Increase de infusion in 25mcg/kg/min after each 5 min until the randomized SAP or if the heart beat is lower than 60. The maximum dose is 200ug/kg/min (ou 0,2 mg/kg/min). If the randomized SAP do not reach the goal pressure with the maximum dose of esmolol, start a infusion of sodium nitroprussiate (NPS). NPS (50mg + SG5% 250ml= 200mcg/ml). No bolus. Start the infusion with 0,2 mcg/kg/min and maintain 0,5 a 5mcg/kg/min. Increase de dose each 15 min to a maximum of 10mcg/kg/min. NOR: (8mg/8ml + SG5% 242ml=32mcg/ml)No bolus. Start 1 to 5 mcg/min to a maximum dose of 20mcg/min.
Drug: Esmolol, NPS or NOR
We use one of the three drug to manipulate the systolic arterial pressure
Drug: manipulation of SAP
Esmolol or NPS or NOR
|
2, 161 to 180 mmHg: Active Comparator
Esmolol, NPS or NOR
|
Drug: Esmolol, Sodium Nitroprussiate (NPS) or Norepinephrine (NOR)
Esmolol(2,5g /10ml + SG5% 240ml = 10mg/ml). Start with a bolus of 500mcg/kg in 1 min (ou 0,5mg/kg)and maintain the dose of 50mcg/kg/min (or 0,05mg/kg/min). Increase de infusion in 25mcg/kg/min after each 5 min until the randomized SAP or if the heart beat is lower than 60. The maximum dose is 200ug/kg/min (ou 0,2 mg/kg/min). If the randomized SAP do not reach the goal pressure with the maximum dose of esmolol, start a infusion of sodium nitroprussiate (NPS). NPS (50mg + SG5% 250ml= 200mcg/ml). No bolus. Start the infusion with 0,2 mcg/kg/min and maintain 0,5 a 5mcg/kg/min. Increase de dose each 15 min to a maximum of 10mcg/kg/min. NOR: (8mg/8ml + SG5% 242ml=32mcg/ml)No bolus. Start 1 to 5 mcg/min to a maximum dose of 20mcg/min.
Drug: Esmolol, NPS or NOR
We use one of the three drug to manipulate the systolic arterial pressure
Drug: manipulation of SAP
Esmolol or NPS or NOR
|
3, 181 to 200 mmHg: Active Comparator
Esmolol, NPS or NOR
|
Drug: Esmolol, Sodium Nitroprussiate (NPS) or Norepinephrine (NOR)
Esmolol(2,5g /10ml + SG5% 240ml = 10mg/ml). Start with a bolus of 500mcg/kg in 1 min (ou 0,5mg/kg)and maintain the dose of 50mcg/kg/min (or 0,05mg/kg/min). Increase de infusion in 25mcg/kg/min after each 5 min until the randomized SAP or if the heart beat is lower than 60. The maximum dose is 200ug/kg/min (ou 0,2 mg/kg/min). If the randomized SAP do not reach the goal pressure with the maximum dose of esmolol, start a infusion of sodium nitroprussiate (NPS). NPS (50mg + SG5% 250ml= 200mcg/ml). No bolus. Start the infusion with 0,2 mcg/kg/min and maintain 0,5 a 5mcg/kg/min. Increase de dose each 15 min to a maximum of 10mcg/kg/min. NOR: (8mg/8ml + SG5% 242ml=32mcg/ml)No bolus. Start 1 to 5 mcg/min to a maximum dose of 20mcg/min.
Drug: Esmolol, NPS or NOR
We use one of the three drug to manipulate the systolic arterial pressure
Drug: manipulation of SAP
Esmolol or NPS or NOR
|
To maintain the tree levels of systolic arterial pressure during de first 24h we will use one of the two strategies:1) infusion of 500 to 1000ml of saline solution and/or norepinephrine solution to increase de systolic pressure or 2) infusion of esmolol or nitroprussiate solution to decrease de pressure. Every patient will have a transcranial doppler study in the first 24h to measure the mean velocity of cerebral arteries.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Contact: Luiz A Nasi, Physician | 55 51 9982 18 44 | lnasi@terra.com.br |
Contact: Miguel Gus | 55 51 81627002 | mgus@mgus.com.br |
Brazil, RS | |
Hospital de Clínicas de Porto Alegre/ UFRGS | Recruiting |
Porto Alegre, RS, Brazil | |
Principal Investigator: L A Nasi, Doctor | |
Sub-Investigator: M Gus, Doctor |
Principal Investigator: | Luiz A Nasi, Physician | Hospital de Clínicas de Porto Alegre / UFRGS |
Responsible Party: | GPPG ( Hospital de Clinicas de Porto Alegre ) |
Study ID Numbers: | HCPA 07-470 |
Study First Received: | February 19, 2009 |
Last Updated: | February 26, 2009 |
ClinicalTrials.gov Identifier: | NCT00848770 History of Changes |
Health Authority: | Brazil: Ethics Committee |
Stroke, Acute Systolic Pressure of Blood |
Neurotransmitter Agents Death Adrenergic alpha-Agonists Adrenergic Agents Cerebral Infarction Stroke Vascular Diseases Benzocaine Central Nervous System Diseases Cardiovascular Agents Ischemia Brain Diseases |
Cerebrovascular Disorders Adrenergic Agonists Esmolol Norepinephrine Vasoconstrictor Agents Adrenergic beta-Antagonists Brain Ischemia Adrenergic Antagonists Peripheral Nervous System Agents Brain Infarction Infarction |
Neurotransmitter Agents Cerebral Infarction Adrenergic Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Brain Diseases Cerebrovascular Disorders Adrenergic Agonists Therapeutic Uses Vasoconstrictor Agents Adrenergic beta-Antagonists Brain Ischemia Cardiovascular Diseases Adrenergic alpha-Agonists |
Sympathomimetics Nervous System Diseases Stroke Vascular Diseases Central Nervous System Diseases Cardiovascular Agents Pharmacologic Actions Esmolol Autonomic Agents Norepinephrine Adrenergic Antagonists Brain Infarction Peripheral Nervous System Agents |